

14:57

FROM-KOS PHARMACEUTICALS, INC.

+3053774076

T-195 P.003/003 F-296

PART B - FEE(S) TRANSMITTAL

APR 14 2004

Complete and send this form, together with applicable fee(s), to: MailMail Stop ISSUE FEE
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450
or Fax (703) 746-4000

INSTRUCTIONS: This form should be used for transmitting the ISSUE FEE and PUBLICATION FEE (if required). Blocks 1 through 4 should be completed where appropriate. All further correspondence including the Patent, advance orders and notification of maintenance fees will be mailed to the current correspondence address as indicated unless corrected below or directed otherwise in Block 1, by (a) specifying a new correspondence address; and/or (b) indicating a separate "FEE ADDRESS" for maintenance fee notifications.

CURRENT CORRESPONDENCE ADDRESS (Note: Legibly mark-up with any corrections or use Block 1)

Note: A certificate of mailing can only be used for domestic mailings of the Fee(s) Transmittal. This certificate cannot be used for any other accompanying papers. Each additional paper, such as an assignment or formal drawing, must have its own certificate of mailing or transmission.

20999

7590

01/15/2004

FROMMER LAWRENCE & HAUG
745 FIFTH AVENUE- 10TH FL.
NEW YORK, NY 10151

Certificate of Mailing or Transmission
I hereby certify that this Fee(s) Transmittal is being deposited with the United States Postal Service with sufficient postage for first class mail in an envelope addressed to the Mail Stop ISSUE FEE address above, or being facsimile transmitted to the USPTO, on the date indicated below.

JAMES G. SILBERTON	(Depositor's name)
<i>[Signature]</i>	(Signature)
4/14/04	(Date)

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/702,263	10/31/2000	Anthony J. Cutie	540541-2013.1	1107

TITLE OF INVENTION: CORE FORMULATION

APPLN. TYPE	SMALL ENTITY	ISSUE FEE	PUBLICATION FEE	TOTAL FEE(S) DUE	DATE DUE
nonprovisional	NO	\$1330	\$0	\$1330	04/15/2004
EXAMINER		ART UNIT	CLASS-SUBCLASS		
GEORGE. KONATA M		1616	424-468000		

1. Change of correspondence address or indication of "Fee Address" (37 CFR 1.363).

- ☐ Change of correspondence address (or Change of Correspondence Address form PTO/SB/123) attached.
- ☐ "Fee Address" indication (or "Fee Address" Indication form PTO/SB/47; Rev 03-02 or more recent) attached. Use of a Customer Number is required.

2. For printing on the patent front page, list (1) the names of up to 3 registered patent attorneys or agents OR, alternatively, (2) the name of a single firm (having as a member a registered attorney or agent) and the names of up to 2 registered patent attorneys or agents. If no name is listed, no name will be printed.

1. KAREN J. MESSICK
2. _____
3. _____

3. ASSIGNEE NAME AND RESIDENCE DATA TO BE PRINTED ON THE PATENT (print or type)

PLEASE NOTE: Unless an assignee is identified below, no assignee data will appear on the patent. Inclusion of assignee data is only appropriate when an assignment has been previously submitted to the USPTO or is being submitted under separate cover. Completion of this form is NOT a substitute for filing an assignment.

(A) NAME OF ASSIGNEE

Aeropharm Technology, Inc.

(B) RESIDENCE (CITY and STATE OR COUNTRY)

18 MAYFIELD AVENUE, EDISON, NJ 08837

Please check the appropriate assignee category or categories (will not be printed on the patent); ☐ individual ☒ corporation or other private group entity ☐ government

4a. The following fee(s) are enclosed:

- ☒ Issue Fee
☐ Publication Fee
☐ Advance Order - # of Copies _____

4b. Payment of Fee(s):

- ☐ A check in the amount of the fee(s) is enclosed.
☐ Payment by credit card. Form PTO-2038 is attached.
☒ The Director is hereby authorized by charge the required fee(s), or credit any overpayment, to Deposit Account Number 500-2543 (enclose an extra copy of this form).

Director for Patents is requested to apply the Issue Fee and Publication Fee (if any) or to re-apply any previously paid issue fee to the application identified above.

(Authorized Signature)

[Signature]

(Date)

4/14/04

NOTE: The Issue Fee and Publication Fee (if required) will not be accepted from anyone other than the applicant, a registered attorney or agent, or the assignee or other party in interest as shown by the records of the United States Patent and Trademark Office.

This collection of information is required by 37 CFR 1.311. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.

SEND TO: Commissioner for Patents, Alexandria, Virginia 22313-1450.


Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

04/15/2004 AWONDAF2 00000008 502543 09702263
01 FC:1501 1330.00 DA

TRANSMIT THIS FORM WITH FEE(S)

PTOL-85 (Rev. 11/03) Approved for use through 04/30/2004.

OMB 0651-0033 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE



KOS PHARMACEUTICALS, INC.

Facsimile Transmission

Wednesday, April 14, 2004

To: Issue Fee Department

Fax: 703.746.4000

From: Jared G. Silberhorn

Voice: 305.523.3663


Fax: 305.377.4076

Re: US Patent App. No. 09/702,263

Total Pages Incl. Cover: 3

Please see attached.

The information contained in this facsimile message is attorney privileged and confidential information intended only for the use of the individual or entity named above. If the reader of this message is not the intended recipient, you are hereby notified that any dissemination, distribution or copy of this communication is strictly prohibited. If you have received this communication in error, please immediately notify us by telephone. Thank you.



14:57

FROM-KOS PHARMACEUTICALS, INC.

+3053774076

T-195 P.002/003 F-296

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Serial No.:

Filing Date:

Docket Number:

Title:

CUTIE, ANTHONY

09/702,263

31 October 2000

540541-2013.1

CORE FORMULATION

MAIL STOP ISSUE FEE

Commissioner For Patents

P.O. Box 1450

Alexandria, VA 22313-1450

ISSUE FEE TRANSMITTAL

Dear Sir:

In connection with the above-referenced United States Patent Application and with regard to the Notice of Allowance mailed 15 January 2004, please charge the requisite Issue Fee of \$1330.00 to our Deposit Account No. 50-2543. A duplicate copy of this letter is enclosed herewith. No additional costs or fees are believed to be due in connection with this application, however, please charge any additional costs or credit any overpayment to this deposit account.

Respectfully submitted,

Kos Pharmaceuticals, Inc.


Karen J. Messick, Esq.

Attorney for Applicants

Registration No. 46,256

Kos Pharmaceuticals, Inc.

1001 Brickell Bay Drive

25th Floor

Miami, Florida 33131

Tel.: (305) 523.3643

Fax.: (305) 377.4076

Date: 4/14/04

CERTIFICATE OF MAILING (37 C.F.R. § 1.8(a))

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to the Commissioner for Patents, Alexandria, VA 22313-1450 on the date indicated below.

Date: 4/14/04

By: 

Jared G. Silberhorn